Background: Despite increasing prevalence of illicit fentanyl use in the US and Canada, preference for fentanyl over other illicit opioids has not been fully characterized. Therefore, we sought to describe changes in illicit opioid preferences over time among people who inject drugs (PWID). Methods: Data were obtained from two prospective cohort studies between 2017 and 2018. Trends in opioid preference over time were examined using bivariable generalized estimating equation (GEE) analysis. Multivariable models were used to identify factors associated with fentanyl preference. Results: Among 732 eligible participants, including 425 (58%) males, the prevalence of preference for fentanyl increased from 4.4% in 2017 to 6.6% in 2018 (Odds Ratio [OR] = 1.27, 95% Confidence Interval [CI]: 1.05–1.52). In a multivariable analysis, younger age (Adjusted Odds Ratio [AOR] = 0.94, 95% CI: 0.92–0.96) and daily crystal methamphetamine injection (AOR = 1.68, 95% CI: 1.01–2.78) were independently associated with preference for fentanyl. The most common reasons for preferring fentanyl included “better high than other opioids” (45%), and “lasts longer than heroin” (27%). Conclusions: The current study has demonstrated that preference for fentanyl has been increasing over time among our sample of PWID who use opioids. Further work is needed to clarify risk factors surrounding transitions to illicit fentanyl.
British Columbia Coroners Service. 2019. Illicit Drug Toxicity Deaths in BC January 1, 2009 – June 30, 2019. Burnaby, British Columbia, Canada: Government of British Columbia, Ministry of Public Safety and Solicitor General; 2019.
2.
SchollL, SethP, KariisaM, WilsonN, BaldwinG.Drug and opioid-involved overdose deaths – United States, 2013–2017. MMWR Morb Mortal Wkly Rep. 2018;67(5152):1419–1427.
3.
National Centre for Health Statistics. 2018. Health, United States, 2017: With Special Feature on Mortality. Hyattsville, MD: Centers for Disease Control and Prevention.
4.
Statistics Canada. 2019. Changes in Life Expectancy by Selected Causes of Death, 2017. Ottawa, Ontario: Statistics Canada.
5.
GomesT, TadrousM, MamdaniMM, PatersonJM, JuurlinkDN.The burden of opioid-related mortality in the United States. JAMA Netw Open. 2018;1(2):e180217.
6.
JonesCM, EinsteinEB, ComptonWM.Changes in synthetic opioid involvement in drug overdose deaths in the United States, 2010–2016. JAMA. 2018;319(17):1819–1821.
7.
HayashiK, MilloyM-J, LysyshynMSubstance use patterns associated with recent exposure to fentanyl among people who inject drugs in Vancouver, Canada: a cross-sectional urine toxicology screening study. Drug Alcohol Depend. 2018;183:1–6.
8.
YoungS, HayashiK, KerrT Association between current opioid agonist therapy use and positive urine drug screen for fentanyl. In Conference of the College of Problems on Drug Dependence. Late-Breaking Abstract; 2019; San Antonio, Texas.
9.
JonesAA, JangK, PanenkaWJRapid change in fentanyl prevalence in a community-based, high-risk sample. JAMA Psychiatry. 2018;75(3):298–300.
10.
SuzukiJ, El-HaddadS.A review: fentanyl and non-pharmaceutical fentanyls. Drug Alcohol Depend. 2017;171:107–116.
11.
CiccaroneD, OndocsinJ, MarsSG. Heroin uncertainties: Exploring users’ perceptions of fentanyl-adulterated and -substituted ‘heroin'. Int J Drug Policy. 2017;46:146–155.
12.
DaniulaityteR, CarlsonRR, JuhascikMP, StrayerKE, SizemoreIE.Street fentanyl use: Experiences, preferences, and concordance between self-reports and urine toxicology. Int J Drug Policy. 2019;71:3–9.
13.
MayerS, BoydJ, CollinsA, KennedyMC, FairbairnN, McNeilR.Characterizing fentanyl-related overdoses and implications for overdose response: findings from a rapid ethnographic study in Vancouver, Canada. Drug Alcohol Depend. 2018;193:69–74.
14.
MoallefS, NosovaE, MilloyMJKnowledge of fentanyl and perceived risk of overdose among persons who use drugs in Vancouver, Canada. Public Health Rep. 2019;134(4):423–431.
15.
MarsSG, OndocsinJ, CiccaroneD.Toots, tastes and tester shots: user accounts of drug sampling methods for gauging heroin potency. Harm Reduct J. 2018;15(1):26.
16.
PalamarJJ, SalomoneA, BigiariniR, VincentiM, AcostaP, TofighiB.Testing hair for fentanyl exposure: a method to inform harm reduction behavior among individuals who use heroin. Am J Drug Alcohol Abuse. 2019;45(1):90–96.
17.
PeiperNC, ClarkeSD, VincentLB, CiccaroneD, KralAH, ZibbellJE.Fentanyl test strips as an opioid overdose prevention strategy: findings from a syringe services program in the Southeastern United States. Int J Drug Policy. 2019;63:122–128.
18.
AmlaniA, McKeeG, KhamisN, RaghukumarG, TsangE, BuxtonJA.Why the FUSS (Fentanyl Urine Screen Study)? A cross-sectional survey to characterize an emerging threat to people who use drugs in British Columbia. Harm Reduct J. 2015;12(1):54.
19.
ParkJN, WeirBW, AllenST, ChaulkP, ShermanSG.Fentanyl-contaminated drugs and non-fatal overdose among people who inject drugs in Baltimore, MD. Harm Reduct J. 2018;15(1):34.
20.
Al-TayyibA, KoesterS, LangeggerS, RavilleL.Heroin and methamphetamine injection: an emerging drug use pattern. Subst Use Misuse. 2017;52(8):1051–1058.
21.
BagleySM, GaiMJ, EarlywineJJ, SchoenbergerSF, HadlandSE, BarocasJA.Incidence and characteristics of nonfatal opioid overdose among youths aged 11 to 24 years by sex. JAMA Netw Open. 2020;3(12):e2030201.
22.
KerrT, FairbairnN, TyndallMPredictors of non-fatal overdose among a cohort of polysubstance-using injection drug users. Drug Alcohol Depend. 2007;87(1):39–45.
23.
SealKH, KralAH, GeeL,et al. Predictors and prevention of nonfatal overdose among street-recruited injection heroin users in the San Francisco Bay area, 1998–1999. Am J Public Health. 2001;91(11):1842–1846.
24.
LarochelleMR, BernsonD, LandT,et al. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study. Ann Intern Med. 2018;169(3):137–145.
25.
British Columbia Coroners Service. Fentanyl-Detected Illicit Drug Toxicity Deaths January 1, 2012 to June 30, 2019. Burnaby, British Columbia, Canada: Government of British Columbia, Ministry of Public Safety and Solicitor General; 2019.
26.
ChengT, SmallW, DongH, NosovaE, HayashiK, DeBeckK.An age-based analysis of nonmedical prescription opioid use among people who use illegal drugs in Vancouver. Subst Abuse Treat Prev Policy. 2018;13(1):41.
27.
MilloyMJ, KerrT, SaltersKIncarceration is associated with used syringe lending among active injection drug users with detectable plasma HIV-1 RNA: a longitudinal analysis. BMC Infect Dis. 2013;13:565.
28.
FairbairnN, RossJ, TrewMInjectable opioid agonist treatment for opioid use disorder: a national clinical guideline. CMAJ. 2019;191(38):E1049–E1056.
29.
MoralesKB, ParkJN, GlickJL, RouhaniS, GreenTC, ShermanSG.Preference for drugs containing fentanyl from a cross-sectional survey of people who use illicit opioids in three United States cities. Drug Alcohol Depend. 2019;204:107547.
30.
EllisMS, KasperZA, CiceroTJ.Twin epidemics: The surging rise of methamphetamine use in chronic opioid users. Drug Alcohol Depend. 2018;193:14–20.
31.
StricklandJC, HavensJR, StoopsWW. A nationally representative analysis of “twin epidemics”: rising rates of methamphetamine use among persons who use opioids. Drug Alcohol Depend. 2019;204:107592.
32.
British Columbia Coroners Service. Illicit drug deaths with methamphetamine involved 2008–2017. Government of British Columbia, Ministry of Public Safety and Solicitor General; 2019.
33.
KariisaM, SchollL, WilsonN, SethP, HootsB.Drug overdose deaths involving cocaine and psychostimulants with abuse potential – United States, 2003–2017. MMWR Morb Mortal Wkly Rep. 2019;68(17):388–395.
34.
TupperKW, McCraeK, GarberI, LysyshynM, WoodE.Initial results of a drug checking pilot program to detect fentanyl adulteration in a Canadian setting. Drug Alcohol Depend. 2018;190:242–245.
35.
Oviedo-JoekesE, BrissetteS, MarshDCDiacetylmorphine versus methadone for the treatment of opioid addiction. N Engl J Med. 2009;361(8):777–786.
36.
Oviedo-JoekesE, GuhD, BrissetteSHydromorphone compared with diacetylmorphine for long-term opioid dependence: a randomized clinical trial. JAMA Psychiatry. 2016;73(5):447–455.
37.
DarkeS.Self-report among injecting drug users: a review. Drug Alcohol Depend. 1998;51(3):253–258.
